COR:NYE-Cencora Inc. (USD)

COMMON STOCK | Medical Distribution |

Last Closing

USD 226.59

Change

-0.95 (-0.42)%

Market Cap

USD 44.01B

Volume

0.71M

Analyst Target

USD 128.75
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and other services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers. This segment also distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; and offers other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment provides international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals; and offers specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was founded in 1871 and is headquartered in Conshohocken, Pennsylvania.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-26 )

Largest Industry Peers for Medical Distribution

Symbol Name Price(Change) Market Cap
CAH Cardinal Health Inc

+0.37 (+0.31%)

USD 28.62B
MCK McKesson Corporation

-0.70 (-0.12%)

N/A
NVG Nuveen AMT Free Municipal Cred..

+0.05 (+0.41%)

N/A
OMI Owens & Minor Inc

+0.25 (+1.97%)

N/A

ETFs Containing COR

KNGU:CA Brompton U.S. Cash Flow K.. 3.85 % 0.00 %

N/A

CAD 6.54M
SAMT The Advisorsa€™ Inner C.. 3.41 % 0.00 %

+0.37 (+0.26%)

USD 0.09B
RUD:CA RBC Quant US Dividend Lea.. 2.93 % 0.43 %

N/A

CAD 0.69B
JMID Janus Henderson Mid Cap G.. 2.24 % 0.00 %

+0.08 (+0.26%)

USD 0.02B
IQSA:F Invesco Markets II PLC - .. 1.48 % 0.00 %

N/A

N/A
IQSE:F Invesco Quantitative Stra.. 1.48 % 0.00 %

N/A

N/A
CSY9:XETRA UBS (Irl) ETF plc - Facto.. 1.48 % 0.00 %

N/A

USD 0.29B
WDMVO:SW UBS (Irl) ETF plc - Facto.. 1.48 % 0.00 %

N/A

USD 0.29B
DEUS Xtrackers Russell US Mult.. 0.00 % 0.18 %

+0.16 (+0.26%)

USD 0.20B
PGAL 0.00 % 0.57 %

N/A

N/A
PPH VanEck Pharmaceutical ETF 0.00 % 0.36 %

+0.15 (+0.26%)

USD 0.61B
VSMV VictoryShares US Multi-Fa.. 0.00 % 0.35 %

+0.09 (+0.26%)

USD 0.12B
RUD-U:CA RBC Quant U.S. Dividend L.. 0.00 % 0.00 %

N/A

N/A
CD47:XETRA 0.00 % 0.00 %

N/A

N/A
BLOV:CA Brompton North American L.. 0.00 % 0.00 %

N/A

CAD 0.01B
CBUF:XETRA iShares MSCI World Health.. 0.00 % 0.00 %

N/A

USD 1.13B

Market Performance

  Market Performance vs. Industry/Classification (Medical Distribution) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 10.33% 60% D- 62% D
Dividend Return 0.74% 50% F 9% A-
Total Return 11.07% 60% D- 55% F
Trailing 12 Months  
Capital Gain 11.35% 60% D- 65% D
Dividend Return 0.75% 50% F 9% A-
Total Return 12.10% 60% D- 59% D-
Trailing 5 Years  
Capital Gain 100.95% 40% F 87% B+
Dividend Return 7.84% 60% D- 22% F
Total Return 108.79% 40% F 87% B+
Average Annual (5 Year Horizon)  
Capital Gain 18.91% 40% F 80% B-
Dividend Return 20.87% 40% F 80% B-
Total Return 1.96% 60% D- 47% F
Risk Return Profile  
Volatility (Standard Deviation) 15.67% 100% F 65% D
Risk Adjusted Return 133.22% 80% B- 99% N/A
Market Capitalization 44.01B 100% F 95% A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

Superior Dividend Growth

This stock has shown top quartile dividend growth in the previous 5 years compared to its sector

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.